Shares of Sana Biotechnology Inc. (SANA) touched a 52-week high of $12 during intraday trading Friday, thanks to the company setting a strong foundation in three therapeutic areas with significant unmet needs - blood cancers, B-cell mediated autoimmune diseases, and type 1 diabetes.
The company's lead drug candidate is SC291, a hypoimmune (HIP), allogeneic, CD19-directed CAR T cell therapy.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.